{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T20:50:13Z","timestamp":1793998213329,"version":"4.8.0"},"reference-count":73,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"vor","delay-in-days":366,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","seizure-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seizure"],"published-print":{"date-parts":[[2019,11]]},"DOI":"10.1016\/j.seizure.2019.07.003","type":"journal-article","created":{"date-parts":[[2019,7,3]],"date-time":"2019-07-03T12:54:46Z","timestamp":1562158486000},"page":"61-70","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":56,"special_numbering":"C","title":["Risks and management of antiepileptic drug induced skin reactions in the adult out-patient setting"],"prefix":"10.1016","volume":"72","author":[{"given":"Thomas","family":"Fowler","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amolak S.","family":"Bansal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dora","family":"Lozs\u00e1di","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.seizure.2019.07.003_bib0005","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1111\/all.12881","article-title":"Drug allergies documented in electronic health records of a large healthcare system","volume":"71","author":"Zhou","year":"2016","journal-title":"Allergy"},{"issue":"April (4)","key":"10.1016\/j.seizure.2019.07.003_bib0010","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1016\/j.jaci.2003.11.032","article-title":"Represcription of penicillin after allergic-like events","volume":"113","author":"Apter","year":"2004","journal-title":"J Allergy Clin Immunol"},{"issue":"July (7)","key":"10.1016\/j.seizure.2019.07.003_bib0015","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1111\/j.1528-1167.2007.01109.x","article-title":"Rash from antiepileptic drugs: influence by gender, age, and learning disability","volume":"48","author":"Alvestad","year":"2007","journal-title":"Epilepsia"},{"issue":"May (20)","key":"10.1016\/j.seizure.2019.07.003_bib0020","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1212\/01.wnl.0000261917.83337.db","article-title":"Comparison and predictors of rash associated with 15 antiepileptic drugs","volume":"68","author":"Arif","year":"2007","journal-title":"Neurology"},{"issue":"November (Pt A)","key":"10.1016\/j.seizure.2019.07.003_bib0025","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.yebeh.2015.09.006","article-title":"Safety and tolerability of lacosamide as adjunctive therapy for adults with partial-onset seizures: analysis of data pooled from three randomized, double-blind, placebo-controlled clinical trials","volume":"52","author":"Biton","year":"2015","journal-title":"Epilepsy Behav"},{"issue":"February (2)","key":"10.1016\/j.seizure.2019.07.003_bib0030","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1111\/joim.12322","article-title":"Personalized medicine approaches in epilepsy","volume":"277","author":"Walker","year":"2015","journal-title":"J Intern Med"},{"issue":"September (7)","key":"10.1016\/j.seizure.2019.07.003_bib0035","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1016\/j.clineuro.2012.01.019","article-title":"Antiepileptic drug-induced skin reactions: a retrospective study and analysis in 3793 Chinese patients with epilepsy","volume":"114","author":"Wang","year":"2012","journal-title":"Clin Neurol Neurosurg"},{"issue":"June (6)","key":"10.1016\/j.seizure.2019.07.003_bib0040","first-page":"765","article-title":"Rates of cutaneous reactions to drugs","volume":"137","author":"Bigby","year":"2001","journal-title":"Arch Dermatol"},{"issue":"July (3)","key":"10.1016\/j.seizure.2019.07.003_bib0045","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1097\/ANA.0b013e318259b46a","article-title":"Cough and bronchospasm after rapid intravenous administration of phenytoin","volume":"24","author":"Dube","year":"2012","journal-title":"J Neurosurg Anesthesiol"},{"issue":"November (11)","key":"10.1016\/j.seizure.2019.07.003_bib0050","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1212\/WNL.30.11.1233","article-title":"Interactions of valproic acid with phenytoin","volume":"30","author":"Bruni","year":"1980","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.seizure.2019.07.003_bib0055","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.jaip.2013.11.005","article-title":"Fever, rash, and systemic symptoms: understanding the role of virus and HLA in severe cutaneous drug allergy","volume":"2","author":"Pavlos","year":"2014","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"4","key":"10.1016\/j.seizure.2019.07.003_bib0060","doi-asserted-by":"crossref","first-page":"e332","DOI":"10.1212\/WNL.0000000000004853","article-title":"Genetic variation in CFH predicts phenytoin-induced maculopapular exanthema in European-descent patients","volume":"90","author":"McCormack","year":"2018","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.seizure.2019.07.003_bib0065","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/tan.13183","article-title":"HLAs: key regulators of T-cell-mediated drug hypersensitivity","volume":"91","author":"Redwood","year":"2018","journal-title":"HLA"},{"issue":"5","key":"10.1016\/j.seizure.2019.07.003_bib0070","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1111\/all.12602","article-title":"Human herpes virus reactivations and dynamic cytokine profiles in patients with cutaneous adverse drug reactions --a prospective comparative study","volume":"70","author":"Chen","year":"2015","journal-title":"Allergy"},{"issue":"4","key":"10.1016\/j.seizure.2019.07.003_bib0075","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1097\/ACI.0000000000000288","article-title":"Relapsing drug-induced hypersensitivity syndrome","volume":"16","author":"Tan","year":"2016","journal-title":"Curr Opin Allergy Clin Immunol"},{"issue":"June (6)","key":"10.1016\/j.seizure.2019.07.003_bib0080","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1111\/all.12410","article-title":"The dynamics of herpesvirus reactivations during and after severe drug eruptions: their relation to the clinical phenotype and therapeutic outcome","volume":"69","author":"Ishida","year":"2014","journal-title":"Allergy"},{"key":"10.1016\/j.seizure.2019.07.003_bib0085","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1212\/01.wnl.0000334295.50403.4c","article-title":"Cross-sensitivity of skin rashes with antiepileptic drug use","volume":"71","author":"Hirsch","year":"2008","journal-title":"Neurology"},{"issue":"6","key":"10.1016\/j.seizure.2019.07.003_bib0090","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1007\/s11882-014-0442-8","article-title":"Skin testing and patch testing in non-IgE-mediated drug allergy","volume":"14","author":"Barbaud","year":"2014","journal-title":"Curr Allergy Asthma Rep"},{"issue":"5","key":"10.1016\/j.seizure.2019.07.003_bib0095","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.therap.2017.01.011","article-title":"Epicutaneous patch testing in delayed drug hypersensitivity reactions induced by antiepileptic drugs","volume":"72","author":"Ben Mahmoud","year":"2017","journal-title":"Therapie"},{"issue":"4","key":"10.1016\/j.seizure.2019.07.003_bib0100","first-page":"299","article-title":"Anticonvulsant drug hypersensitivity","volume":"12","author":"Galindo","year":"2002","journal-title":"J Investig Allergol Clin Immunol"},{"issue":"3","key":"10.1016\/j.seizure.2019.07.003_bib0105","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1111\/cod.12269","article-title":"Non-irritant concentrations and amounts of active ingredient in drug patch tests","volume":"71","author":"Brajon","year":"2014","journal-title":"Contact Derm"},{"issue":"March (10)","key":"10.1016\/j.seizure.2019.07.003_bib0110","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/1471-2334-10-49","article-title":"Is the drug-induced hypersensitivity syndrome (DIHS) due to human herpesvirus 6 infection or to allergy-mediated viral reactivation? Report of a case and literature review","volume":"6","author":"Gentile","year":"2010","journal-title":"BMC Infect Dis"},{"issue":"January (1)","key":"10.1016\/j.seizure.2019.07.003_bib0115","doi-asserted-by":"crossref","first-page":"153","DOI":"10.2165\/00003495-199447010-00009","article-title":"A reappraisal of its antiviral activity, pharmacokinetic properties and therapeutic efficacy","volume":"47","author":"Wagstaff","year":"1994","journal-title":"Drugs"},{"issue":"2","key":"10.1016\/j.seizure.2019.07.003_bib0120","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1034\/j.1398-9995.2000.00467.x","article-title":"Severe hypersensitivity syndrome to lamotrigine confirmed by lymphocyte stimulation in vitro","volume":"55","author":"Schaub","year":"2000","journal-title":"Allergy"},{"issue":"3","key":"10.1016\/j.seizure.2019.07.003_bib0125","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1111\/cea.13076","article-title":"Sensitivity and specificity of the lymphocyte transformation test in drug reaction with eosinophilia and systemic symptoms causality assessment","volume":"48","author":"Caba\u00f1as","year":"2018","journal-title":"Clin Exp Allergy"},{"issue":"August (4)","key":"10.1016\/j.seizure.2019.07.003_bib0130","doi-asserted-by":"crossref","first-page":"451","DOI":"10.5021\/ad.2016.28.4.451","article-title":"Immunohistochemical comparison of IL-36 and the IL-23\/Th17 Axis of generalized pustular psoriasis and acute generalized exanthematous pustulosis","volume":"28","author":"Song","year":"2016","journal-title":"Ann Dermatol"},{"issue":"12","key":"10.1016\/j.seizure.2019.07.003_bib0135","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.1111\/all.12299","article-title":"Absence of cross-reactivity to carbapenems in patients with delayed hypersensitivity to penicillins","volume":"68","author":"Romano","year":"2013","journal-title":"Allergy"},{"key":"10.1016\/j.seizure.2019.07.003_bib0140","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1097\/00005792-199505000-00004","article-title":"Carbamazepine hypersensitivity syndrome: report of 4 cases and review of the literature","volume":"74","author":"De Vries","year":"1995","journal-title":"Medicine"},{"key":"10.1016\/j.seizure.2019.07.003_bib0145","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1111\/all.12161","article-title":"Desensitization in delayed drug hypersensitivity reactions \u2013 an EAACI position paper of the Drug Allergy Interest Group","volume":"68","author":"Scherer","year":"2013","journal-title":"Allergy"},{"key":"10.1016\/j.seizure.2019.07.003_bib0150","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.jcf.2011.02.002","article-title":"Rapid desensitization for non-immediate reactions in patients with cystic fibrosis","volume":"10","author":"Whitaker","year":"2011","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.seizure.2019.07.003_bib0155","article-title":"Cotrimoxazole for prophylaxis or treatment of opportunistic infections of HIV\/AIDS in patients with previous history of hypersensitivity to cotrimoxazole","volume":"2","author":"Lin","year":"2007","journal-title":"Cochrane Database Syst Rev"},{"issue":"June","key":"10.1016\/j.seizure.2019.07.003_bib0160","article-title":"Immunological mechanisms in allergic diseases and allergen tolerance: the role of treg cells","author":"Calzada","year":"2018","journal-title":"J Immunol Res"},{"key":"10.1016\/j.seizure.2019.07.003_bib0165","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1159\/000078583","article-title":"Successful desensitization to \ufb01xed drug eruption: the presence of CD25+ CD4+ T cells in the epidermis of \ufb01xed drug eruption lesions may be involved in the induction of desensitization","volume":"209","author":"Teraki","year":"2004","journal-title":"Dermatology"},{"key":"10.1016\/j.seizure.2019.07.003_bib0170","series-title":"Rash in multicenter trials of lamotrigine in mood disorders: clinical relevance and management","first-page":"1012","author":"Calabrese","year":"2002"},{"issue":"1","key":"10.1016\/j.seizure.2019.07.003_bib0175","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1590\/abd1806-4841.20175070","article-title":"Identifying the incidence of rash, Stevens-Johnson syndrome and toxic epidermal necrolysis in patients taking lamotrigine: a systematic review of 122 randomized controlled trials","volume":"92","author":"Bloom","year":"2017","journal-title":"An Bras Dermatol"},{"issue":"December (12)","key":"10.1016\/j.seizure.2019.07.003_bib0180","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.4088\/JCP.v65n1219b","article-title":"Two cases of acneiform eruption associated with lamotrigine","volume":"65","author":"Nielsen","year":"2004","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.seizure.2019.07.003_bib0185","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1111\/ijd.12570","article-title":"Association of HLA-B*1502 allele with lamotrigine-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in Han Chinese subjects: a meta-analysis","volume":"54","author":"Zeng","year":"2015","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.seizure.2019.07.003_bib0190","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/s00228-014-1764-0","article-title":"Clinical features of, and genetic predisposition to drug-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in a single Korean tertiary institution patients-investigating the relation between the HLA -B*4403 allele and lamotrigine","volume":"71","author":"Park","year":"2015","journal-title":"Eur J Clin Pharmacol"},{"issue":"May (5)","key":"10.1016\/j.seizure.2019.07.003_bib0195","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/j.anai.2017.02.011","article-title":"HLA-A*31:01 and lamotrigine-induced severe cutaneous adverse drug reactions in a Korean population","volume":"118","author":"Kim","year":"2017","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"June (23)","key":"10.1016\/j.seizure.2019.07.003_bib0200","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1212\/WNL.0000000000004008","article-title":"HLA-A*24:02 as a common risk factor for antiepileptic drug-induced cutaneous adverse reactions","volume":"88","author":"Shi","year":"2017","journal-title":"Neurology"},{"issue":"August (8)","key":"10.1016\/j.seizure.2019.07.003_bib0205","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1007\/s00115-006-2060-8","article-title":"The use of lamotrigine in female patients","volume":"78","author":"Schmitz","year":"2007","journal-title":"Nervenarzt"},{"issue":"5","key":"10.1016\/j.seizure.2019.07.003_bib0210","first-page":"27","article-title":"Rechallenge with lamotrigine after a rash: a prospective case series and review of the literature","volume":"7","author":"Aiken","year":"2010","journal-title":"Psychiatry (Edgmont)"},{"issue":"2","key":"10.1016\/j.seizure.2019.07.003_bib0215","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1017\/S1461145708009504","article-title":"Lamotrigine-associated rash: To rechallenge or not to rechallenge?","volume":"12","author":"Lorberg","year":"2009","journal-title":"Int J Neuropsychopharmacol"},{"issue":"August (2)","key":"10.1016\/j.seizure.2019.07.003_bib0220","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1212\/WNL.49.2.542","article-title":"Risk of serious cutaneous disorders after initiation of use of phenytoin, carbamazepine, or sodium valproate: a record linkage study","volume":"49","author":"Tennis","year":"1997","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.seizure.2019.07.003_bib0225","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.eplepsyres.2006.02.006","article-title":"Association of anticonvulsant hypersensitivity syndrome with Herpesvirus 6, 7","volume":"70","author":"Oskay","year":"2006","journal-title":"Epilepsy Res"},{"issue":"4","key":"10.1016\/j.seizure.2019.07.003_bib0230","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1097\/01.fpc.0000199500.46842.4a","article-title":"Genetic susceptibility to carbamazepine-induced cutaneous adverse drug reactions","volume":"16","author":"Hung","year":"2006","journal-title":"Pharmacogenet Genomics"},{"issue":"April (4)","key":"10.1016\/j.seizure.2019.07.003_bib0235","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1002\/cpt.1004","article-title":"Clinical pharmacogenetics implementation consortium guideline for HLA genotype and use of carbamazepine and oxcarbazepine: 2017 update","volume":"103","author":"Phillips","year":"2018","journal-title":"Clin Pharmacol Ther"},{"issue":"3","key":"10.1016\/j.seizure.2019.07.003_bib0240","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1111\/j.1468-3083.2011.04418.x","article-title":"A patch testing and cross-sensitivity study of carbamazepine-induced severe cutaneous adverse drug reactions","volume":"27","author":"Lin","year":"2013","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"December (6)","key":"10.1016\/j.seizure.2019.07.003_bib0245","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1006\/ebeh.2000.0126","article-title":"Oxcarbazepine for treatment of partial epilepsy: a review and recommendations for clinical use","volume":"1","author":"Schmidt","year":"2000","journal-title":"Epilepsy Behav"},{"issue":"December (12)","key":"10.1016\/j.seizure.2019.07.003_bib0250","first-page":"1597","article-title":"Oxcarbazepine placebo-controlled, dose-ranging trial in refractory partial epilepsy","volume":"41","author":"Barcs","year":"2000","journal-title":"Epilepsia"},{"issue":"August (2)","key":"10.1016\/j.seizure.2019.07.003_bib0255","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.pediatrneurol.2014.03.021","article-title":"Human leukocyte antigen genotypes and trial of desensitization in patients with oxcarbazepine-induced skin rash: a pilot study","volume":"51","author":"Lee","year":"2014","journal-title":"Pediatr Neurol"},{"issue":"January (1)","key":"10.1016\/j.seizure.2019.07.003_bib0260","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1212\/WNL.0000000000003453","article-title":"Risk and association of HLA with oxcarbazepine-induced cutaneous adverse reactions in Asians","volume":"88","author":"Chen","year":"2017","journal-title":"Neurology"},{"issue":"3","key":"10.1016\/j.seizure.2019.07.003_bib0265","doi-asserted-by":"crossref","first-page":"349","DOI":"10.2217\/pgs.09.162","article-title":"Common risk allele in aromatic antiepileptic-drug induced Stevens-Johnson syndrome and toxic epidermal necrolysis in Han Chinese","volume":"11","author":"Hung","year":"2010","journal-title":"Pharmacogenomics"},{"issue":"December (12)","key":"10.1016\/j.seizure.2019.07.003_bib0270","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1007\/s40264-017-0576-4","article-title":"Safety profile of eslicarbazepine acetate as add-on therapy in adults with refractory focal-onset seizures: from clinical studies to 6 years of post-marketing experience","volume":"40","author":"Gama","year":"2017","journal-title":"Drug Saf"},{"issue":"Oct-Dec (4)","key":"10.1016\/j.seizure.2019.07.003_bib0275","doi-asserted-by":"crossref","first-page":"271","DOI":"10.4103\/0976-500X.142456","article-title":"Cutaneous adverse drug reaction type erythema multiforme major induced by eslicarbazepine","volume":"5","author":"Massot","year":"2014","journal-title":"J Pharmacol Pharmacother"},{"issue":"September (5)","key":"10.1016\/j.seizure.2019.07.003_bib0280","doi-asserted-by":"crossref","first-page":"229","DOI":"10.23822\/EurAnnACI.1764-1489.37","article-title":"Leiria-Pinto P Patch testing in a case of eslicarbazepine and carbamazepine induced cutaneous reaction","volume":"50","author":"Finelli","year":"2018","journal-title":"Eur Ann Allergy Clin Immunol"},{"issue":"July (7)","key":"10.1016\/j.seizure.2019.07.003_bib0285","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1007\/s00228-017-2250-2","article-title":"Influence of genetic and non-genetic factors on phenytoin-induced severe cutaneous adverse drug reactions","volume":"73","author":"Yampayon","year":"2017","journal-title":"Eur J Clin Pharmacol"},{"issue":"5","key":"10.1016\/j.seizure.2019.07.003_bib0290","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1111\/j.1468-3083.2006.01510.x","article-title":"Stevens-Johnson syndrome in two patients treated with cranial irradiation and phenytoin","volume":"20","author":"Aydin","year":"2006","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.seizure.2019.07.003_bib0295","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.phrs.2016.11.027","article-title":"Significant HLA class I type associations with aromatic antiepileptic drug (AED)-induced SJS\/TEN are different from those found for the same AED-induced DRESS in the Spanish population","volume":"115","author":"Ram\u00edrez","year":"2017","journal-title":"Pharmacol Res"},{"issue":"4","key":"10.1016\/j.seizure.2019.07.003_bib0300","doi-asserted-by":"crossref","first-page":"399","DOI":"10.2217\/pgs.11.165","article-title":"Genome-wide mapping for clinically relevant predictors of lamotrigine- and phenytoin-induced hypersensitivity reactions","volume":"13","author":"McCormack","year":"2012","journal-title":"Pharmacogenomics"},{"issue":"5","key":"10.1016\/j.seizure.2019.07.003_bib0305","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1001\/jama.2014.7859","article-title":"Genetic variants associated with phenytoin-related severe cutaneous adverse reactions","volume":"312","author":"Chung","year":"2014","journal-title":"Jama"},{"issue":"6","key":"10.1016\/j.seizure.2019.07.003_bib0310","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.ejpn.2007.03.001","article-title":"Phenytoin desensitization monitored by antigen specific T cell response using carboxyfluorescein succinimidyl ester dilution assay","volume":"11","author":"Okumura","year":"2007","journal-title":"Eur J Paediatr Neurol"},{"issue":"December","key":"10.1016\/j.seizure.2019.07.003_bib0315","article-title":"Antiepileptic drug monotherapy for epilepsy: a network meta-analysis of individual participant data","volume":"12","author":"Nevitt","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"issue":"April (7)","key":"10.1016\/j.seizure.2019.07.003_bib0320","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1212\/01.WNL.0000156354.20227.F0","article-title":"Risk of Stevens-Johnson syndrome and toxic epidermal necrolysis in new users of antiepileptics","volume":"64","author":"Mockenhaupt","year":"2005","journal-title":"Neurology"},{"issue":"October (10)","key":"10.1016\/j.seizure.2019.07.003_bib0325","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1111\/epi.13509","article-title":"Association of HLA genotypes with phenobarbital hypersensitivity in children","volume":"57","author":"Manuyakorn","year":"2016","journal-title":"Epilepsia"},{"issue":"November","key":"10.1016\/j.seizure.2019.07.003_bib0330","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.seizure.2017.09.019","article-title":"Safety of intravenous lacosamide in critically ill children","volume":"52","author":"Welsh","year":"2017","journal-title":"Seizure"},{"issue":"2","key":"10.1016\/j.seizure.2019.07.003_bib0335","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1002\/epi4.12053","article-title":"DRESS syndrome: A case of cross-reactivity with lacosamide?","volume":"2","author":"Fong","year":"2017","journal-title":"Epilepsia Open"},{"key":"10.1016\/j.seizure.2019.07.003_bib0340","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1007\/s12028-010-9501-8","article-title":"The use of lacosamide in refractory status epilepticus","volume":"14","author":"Goodwin","year":"2011","journal-title":"Neurocrit Care"},{"issue":"September (9)","key":"10.1016\/j.seizure.2019.07.003_bib0345","first-page":"1179","article-title":"Multicenter double-blind, randomized, placebo-controlled trial of levetiracetam as add-on therapy in patients with refractory partial seizures","volume":"41","author":"Shorvon","year":"2000","journal-title":"European Levetiracetam Study Group. Epilepsia."},{"issue":"December (12)","key":"10.1016\/j.seizure.2019.07.003_bib0350","doi-asserted-by":"crossref","first-page":"2178","DOI":"10.1111\/epi.13925","article-title":"The risk of Stevens-Johnson syndrome and toxic epidermal necrolysis in new users of antiepileptic drugs","volume":"58","author":"Frey","year":"2017","journal-title":"Epilepsia"},{"issue":"December (6)","key":"10.1016\/j.seizure.2019.07.003_bib0355","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1016\/j.anai.2016.09.443","article-title":"Antiepilepsy drugs and the immune system","volume":"117","author":"Godhwani","year":"2016","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"December (12)","key":"10.1016\/j.seizure.2019.07.003_bib0360","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1111\/j.1600-0625.2008.00748.x","article-title":"Predicting possible zonisamide hypersensitivity syndrome","volume":"17","author":"Neuman","year":"2008","journal-title":"Exp Dermatol"},{"key":"10.1016\/j.seizure.2019.07.003_bib0365","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.2217\/pgs.13.180","article-title":"Specific HLA types are associated with antiepileptic drug-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in Japanese subjects","volume":"14","author":"Kaniwa","year":"2013","journal-title":"Pharmacogenomics"}],"container-title":["Seizure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1059131119302031?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1059131119302031?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T01:53:08Z","timestamp":1761011588000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1059131119302031"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11]]},"references-count":73,"alternative-id":["S1059131119302031"],"URL":"https:\/\/doi.org\/10.1016\/j.seizure.2019.07.003","relation":{},"ISSN":["1059-1311"],"issn-type":[{"value":"1059-1311","type":"print"}],"subject":[],"published":{"date-parts":[[2019,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Risks and management of antiepileptic drug induced skin reactions in the adult out-patient setting","name":"articletitle","label":"Article Title"},{"value":"Seizure","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.seizure.2019.07.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Published by Elsevier Ltd on behalf of British Epilepsy Association.","name":"copyright","label":"Copyright"}]}}